The detection of drugs of abuse in urine by four commercial immunoassay systems (TDx, BCL and PFI-20 opiates, and PFI-20 morphine) and one commercial TLC system (Toxi-Lab) was investigated and results compared with those obtained by a dual-column capillary GC system. The TDx system was the most reliable method for preliminary screening of urines for opiates; all the commercial immunoassay systems gave some results which were at variance with those of the Gc. The GC method proved to be more reliable than the commercial TLC system in discriminating between the different opiates and is recommended for identification of drugs of abuse in urine specimens in which positive results have been obtained with preliminary screening procedures.
The marked growth in drug misuse in the UK has resulted in a steady increase in the number of requests for screening urine samples for the presence of opiates and other drugs of abusc.l? Many of the samples are from drug abusers who have been prescribed dihydrocodeine or methadone to alleviate the symptoms associated with withdrawal from heroin. It is desirable to check that drug abusers are taking the prescribed medication and not continuing to take drugs such as heroin. For this reason it is important to distinguish between opioids used in treatment and morphine resulting from the metabolism of heroin. Some patients may be taking over-thecounter preparations containing morphine, codeine or pholeodine; morphine may also be present as a metabolite of codeine.
Several screening methods for opiates and related drugs are now commercially available including the Emit (Syva), TDx (Abbott Laboratories Ltd) , PFI-20 (Perkin-Elmer Ltd), Abuscreen (Roche Products Ltd) and Diagnostic Products Corporation immunoassay systems, the BCL (Boehringer Corporation Ltd) and Agglutex (Roche Products Ltd) opiates haemagglutination methods, and the Toxi-Lab thin-layer chromatography system (Analytical Systems Inc). Some of these assays are highly sensitive but have only limited specificity, while others have better specificity but do not have the desired sensitivity. I.) H Correspondence: D Simpson 172 For example, the Emit, TDx, PFI-20 and BCL tests for opiates cannot distinguish between morphine, codeine and dihydrocodeine. The Toxi-Lab system can be used to identify individual opiates, but preliminary hydrolysis of the glucuronide conjugate may be necessary to achieve the desired sensitivity for morphine in urine samples. Methadone can also be identified by the Toxi-Lab system and can be detected by specific immunoassay techniques using the Emit and PFI-20 systems. A PFI-20 immunoassay system with claimed specificity for morphine is available.
The Emit system is widely used for screening urines for drugs of abuse. The opiates assay (limit of detection for unconjugated morphine, O'3 mg/ L) may be performed on an analyser bought or hired from the manufacturer and the reagents can be adapted for use on a centrifugal analyser," thereby reducing the reagent cost per sample.
Manufacturers of the TDx,IO PFI-20,11 BCL,12 Emit!' and Toxi-Lab" systems recommend that positive results for drugs of abuse should be confirmed by other procedures.
There are many publications on the use of the Emit system 5.9 . 15 and it is reported to be a reliable procedure. 16 Evaluations of the BCL opiates? and Toxi-Lab systerns'" have been reported but we know of no reports of the performance of the PFI-20 systems and there is no published data on the use of the TDx system in a laboratory with a large workload."
In this study urine samples from drug abusers were screened using the TDx, PFI-20 and BCL opiates systems, the PFI-20 morphine system and the Toxi-Lab system. Results of these assays were compared with results obtained by a dual-column capillary GC system in order to select suitable analytical procedures for the routine detection of drugs of abuse in urine. be set by the user between 0·2 mg/L and 1·0 mg/L; the setting used in this study was 0·2 mg/L, Results are printed as 'less than threshold' or 'greater than or equal to threshold', and numcrical results may be selected. In addition to morphine, the method detects codeine and dihydrocodeine with estimated cross-reactivities of 118-138";" and 48-61 %, respectively; methadone has a cross-reactivity of < 0·1 %.
Material and methods

CHEMICALS
PFI-20 SYSTEM This polarisation fluoroimmunoassay system (Perkin Elmer Ltd, Beaconsfield, UK) consists of the LS-20 autosampling system in which the single reagent is dispensed, mixed and incubated with urine samples in a 40-position carousel, and the LS-20 filter fluorimeter in which polarisation measurements are performed. In the screening tests the 'rnillipolarisation' units for tests are printed and compared with those of a kit standard to give a positive or negative result. The opiates screening test uses a standard of 10·0 mg/L morphine, Cross-reactivities of 283%, 260% and < 0·1 % for codeine, dihydrocodeine and methadone, respectively, are given by the manufacturers. The morphine screen uses a standard of 1·0 mg/L; cross-reactivities for codeine and dihydrocodeinc are claimed by the manufacturerstobe <0·1%.
BeL OPIATES TEST The assay (Drug Test Opiates, Boehringer Biochemia Robin) was performed according to the instructions'? of the manufacturer (Boehringer Corporation Ltd, Lewes, UK); all samples were allowed to reach room temperature and were centrifuged for 10 min at 2600 rpm before analysis.' The manufacturer quotes a detection limit of 0·05 mg/L for 'free' morphine (0'2mg/L for total morphine) with cross-reactivities of 100%, 25% and < 0·1 % for codeine, dihydrocodeine and methadone, respectively.
TOXI-LAB SYSTEM
Toxi-Lab A analysis was performed according to the instructions of the manufacturer (Mercia Diagnostics Ltd, Guildford, UK).6 Detection limits of 1·0 rng/L for dihydrocodeine and unconjugatcd morphine, and 0·5 mg/L for codeine and methadone, are quoted. If a positive result was obtained by the BCL opiates test but no drugs were detected by thc Toxi-Lab A procedure, urine samples (5 rnl.) were incubated with [J-glucuronidase (3 mg) for 5 hat 56'C to convert any morphinc-Jvglucuronidc present to morphine." After incubation, the extraction and concentration of drugs were carried out by the standard Toxi-Lab A procedures." The disc containing the urine extract was then inserted into the first channel of a Blank A chromatogram and placed in a developing jar containing 2 mL hexane to remove lipid artifacts." When the solvent front had migrated to the 10 em line, the chromatogram was dried, the disc transferred to the second channel and a standard morphine disc inserted in the third channel. The chromatogram was then developed with 3 mL of developing solvent A containing 50 JlL of ammonium hydroxide (A50). Detection was carried out using the standard Toxi-Lab A procedure."
If the presence of dihydrocodeine, codeine or morphine was suggested by the Toxi-Lab system, the analysis was repeated using a double migration development procedure to separate the opiates." A second 5 mL portion of urine was processed and the disc containing the drugs was inserted in a Blank A chromatogram together with dihydrocodeinc, codeine and morphine standard discs. The chromatogram was developed using 3 mL of Developing Solvent B containing 100 JlL of ammonium hydroxide (B I00) first and then 3 mL of Developing Solvent A containing 50 JlL of ammonium hydroxide (A50). Detection was carried out using the standard Toxi-Lab A procedure."
The identification of individual opiates may be improved by the use of confirmatory tests. The presence of morphine or codeine may be confirmed by dipping the chromatogram in sodium hydroxide solution after Stage IV of the detection process (Dragendorlf's reagent); the spots change colour from brown to green." In a confirmatory test for morphine, a chromatogram developed in solvent A50 is dipped in silver nitrate solution (Dip B2) and heated; morphine shows as a grey spot if present in the unknown, and in the morphine standard run in parallel."
The presence of benzoylecgonine, a major metabolite of cocaine, may be tested for by a special procedure" in samples where cocaine is detected by the standard Toxi-Lab A procedure, or if cocaine abuse is suspected by the requesting elinician.
CAPILLARY GC SYSTEM
The GC screening system consisted of a Hewlett-Packard 5890 GC (Hewlett-Packard Ltd, Wokingham, UK) with two capillary columns. An SE-54 column (25 m x 0·2 mm ID, film thickness 0·33 11m, Hewlett-Packard) was connected to a flame ionisation detector, and an OV-17 column (30 m x 0·25 mm ID, film thickness 0·25 uru, J and W Scientific Inc, Rancho Cordova, California, USA) was connected to a nitrogen-phosphorus detector. Helium flow rates through the two columns measured at 100'C were 0·76 and 1·44 mLjrnin respectively. Both columns were connected to a single split injector using a two-hole graphitised vespel ferrule. Split ratio was approximately 40: I. Conditions were: injector temperature 280"C; detector temperature 320'C; oven program 180-280C at Tlmin, then holding at 280"C for 20 min. Output was to a REC-2 twinchannel recorder (Pharmacia Ltd, Milton Keynes, UK).
Several techniques of sample preparation for GC analysis were compared: buffered extraction into ether or dichloromethane, extraction with SEP-PAC C l8 cartridges (Waters Chromatography Division, Millipore UK Ltd, Harrow, UK) and extraction using Toxi-Tubes A (Mercia Diagnostics Ltd, Guildford, UK). These are capped alkaline extraction tubes that have volume markings and contain reagents for the extraction of basic and neutral drugs. Toxi-Tubes A proved to be superior to the other techniques, both in the recovery of drugs from spiked urine samples and in discrimination against endogenous compounds (data not shown).
Urine (5 mL) was added to a Toxi-Tube A and mixed for 5 min on a Spiramix rotary mixer. After centrifugation, 1·0 mL of the solvent layer was transferred to a 10 mL conical glass tube which had previously been soaked in I mol/L HCI followed by methanol. Solvent was evaporated at 50"C under nitrogen; as soon as all solvent had evaporated, the residue was dissolved in 40 JlL ethyl acetate (containing 0·5 g/L 2-amino-5chlorobenzophenone internal standard) and I JlL injected into the Gc.
Retention times and heights of all peaks on both channels were measured. Retention times relative to the internal standard were calculated and compared with an index of relative retention times that had been prepared previously by injection of pure drug extracts (I g/L). The identification of a drug was tentatively made when its relative retention times on both columns matched those of the standard. The following ratio was also calculated: This ratio depends on the response of each column and detector system to the individual drugs. In practice, it varied too greatly with column performance to be of use in absolute identification, but it did provide a useful check on identity. If the results suggested the presence of amphetamines or other volatile drugs, the injection was repeated using an alternative oven programme: 100-280'C at 15 /min, then holding at 280C for 5 min.
The identity of morphine, codeine and dihydroeodeine was confirmed by heating the dried residue for 10 min at 60C in a stoppered tube with acetic anhydride (10 ilL) and pyridine (2 ilL). Reagents were evaporated under nitrogen at 60C; the residue was dissolved in 40 ILL ethyl acetate (containing 0·5 giL 2-amino-5-ehlorobenzophenone internal standard) and I ilL was injected into the Gc. Relative retention times of the acetyl derivatives on both channels were calculated and compared with those of standards.
An approximate measure of the concentration of morphine, codeine, dihydroeodeine and methadone was obtained by calculating the ratio of peak height relative to the internal standard, and comparing this with values given by urines spiked with standard concentrations of the drugs. Reporting limits for the GC system were: unconjugated morphine, I· 3 mgjl; codeine, O' Smg/L; dihydrocodeine, 0·6 rng/L; methadone, 0·4 mg/L.
Urine samples from patients on methadone or dihydrocodeine each gave a single metabolite peak. Since pure metabolite was not available for calibration, peak height relative to the internal
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standard was used as an indication of the concentration of metabolite present for the purposes of comparison.
Results
DIHYDROCODEINE
Of 24 samples in which dihydrocodeine was detected as the only opioid present by GC, the Toxi-Lab system gave positive results for 12 samples with a further 3 borderline results (Table  I) . Of 14 samples in which dihydrocodeine was detected in addition to codeine, dcxtropropoxyphene, methadone or morphine, the Toxi-Lab system identified the drug in 9 samples with one borderline result. Failure to detect dihydrocodeine by Toxi-Lab could occur at any concentration of the drug, but particularly when the concentration was low « 4 rng/L). In some samples the presence of dihydrocodeine was not detected because of interference by metabolites of other drugs, e.g. nortriptyline and dextropropoxyphene. In 2 samples dihydrocodeinc was mistaken for codeine despite re-analysis using a double migration development system (run with B I00 and then A50). In 3 samples hydrolysis with If-glucuronidase and developing with A50 solvent failed to distinguish between dihydrocodeine and morphine ( The BCL opiates assay gave positive results for 16 and borderline results for 4 of the 24 samples in which dihydrocodeine was the only opioid detected by GC (Table I) . The test failed to detect the presence of opiates in 4 samples, but positive results were achieved after the samples had been diluted I: 9 with distilled water in an attempt to overcome possible antigen excess. Positive results were obtained for 13 of the 14 samples in which other opioids were also detected by Gc.
The TDx opiates method was the only screening procedure to respond positively to all 24 urines in which dihydrocodeine was detected by GC (Table I) . The PFI-20 opiates method gave positive results for 21 of these samples and for all 14 samples in which other opioids were also detected by Gc.
Positive responses by the PFI-20 morphine method were unexpected; they usually occurred at higher concentrations of dihydrocodeine but were also seen in some samples in which the concentrations of dihydrocodeine and metabolite were relatively low. For both parent drug and metabolite, concentrations greater than the median value gave II positives out of 12 samples, and concentrations lower than the median gave 5 positives out of 12 samples. CODEINE The GC system detected codeine in 4 samples (Table I) . It was identified in all these samples by the Toxi-Lab system. Positive results were obtained for the 4 samples by the TDx and BCL assays. Both PFI-20 methods gave negative results for the sample in which codeine was the only opioid detected by Gc. (Tables I and 2 ); the Toxi-Lab system identified morphine in 2 of these. Positive results were given by the TDx, BCL and both PFI-20 systems for the sample in which morphine was the only opioid detected by Gc.
MORPHINE
Morphine was detected by GC in 3 samples
METHADONE
Methadone was detected by GC as the only opioid in 21 samples (Table I) ; the drug was present together with dihydrocodeine in 10 samples and with pethidine in one sample. The Toxi-Lab system detected methadone in all these urines, although in 2 cases a borderline result was reported. In addition, the Toxi-Lab system detected methadone in 2 samples in which only dihydrocodeine, or codeine and dextropropoxyphene, were detected by GC; a borderline result was obtained from a third sample in which no opioids were detected by Gc.
Of 21 samples in which methadone was the only opioid detected by Gc, positive results were obtained in 5 samples by the TDx and PFI-20 opiates methods, while positive or borderline results were obtained in 4 samples by the BCL method. All three methods report cross-reactivities for methadone of < 0·1 %, but have greater sensitivity for morphine than the GC system. Positive results for these samples by the immunoassay systems did not appear to be directly related to the concentration of methadone or its metabolite determined by GC; for samples giving positive or borderline results the methadone concentration range was 0·!j-4·0 rng/L while for samples giving negative results the range was 0,5-13·0 mg/L, There was one borderline posmve result from the PFI-20 morphine method in a sample which contained methadone alone by Gc. DEXTROPROPOXYPHENE Dextropropoxyphene metabolites were detected in 4 samples by the GC system (Table 1 ). In 2 of these samples the metabolites were detected by the Toxi-Lab system, and in a third a borderline result was reported. The Toxi-Lab system failed to detect the metabolites in a fourth sample in which codeine was also detected by GC, but a borderline result was obtained for a sample in which the metabolites were not detected by Gc.
Positive results were obtained by the TDx, PFl-20 and BCL opiates methods for the sample in which dextropropoxyphene was the only opioid detected by Gc.
PETHIDINE
In one urine sample in which pethidine and methadone were detected by GC, both drugs were identified by the Toxi-Lab system (Table I) . PHOLCODINE A borderline result for pholeodine was obtained by GC for one sampIc in which no drugs were detected by the Toxi-Lab system, but positive results for opiates were obtained by the TDx, PFI-20 and BCL methods.
OPIOIDS NOT DETECTED BY GC
No opioids were detected by the GC system in 19 urines (Table 1 ). In one of these samples a borderline result was obtained for methadone by the Toxi-Lab method. The PFl-20 opiates method gave 6 positive results, the TDx and BCL methods gave 3 positive results, and 2 positive results were obtained by the PFI-20 morphine method. Positive results by the immunoassay methods were not associated with any unusual capillary GC or Toxi-Lab pattern nor with any one particular patient; most of them, especially those which gave high TDx values, were from the general practice drug abusers.
NON-OPIOID DRUGS
The performance of the Toxi-Lab system in the detection of non-opioid drugs is compared with that of GC in Table 3 . The Toxi-Lab system detected amphetamine, paracetamol, phenolphthalein and trimethoprim in most of the samples in which these drugs were detected by Gc. It failed to identify temazepam in 13 samples in which the presence of the drug was demonstrated by Gc. The Toxi-Lab system is unable to identify metronidazole.
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CONSISTENT PATTERNS BY GC
Two major patterns were seen in capillary GC analysis. Inspection of the data showed that one pattern was associated with temazepam and the other with dextropropoxyphene. Two samples were analysed by gas chromatography-mass spectrometry (GC-MS): one of the peaks associated with dextropropoxyphene was a metabolite; one of the peaks associated with temazepam was the corresponding benzophenone (2-methylamino-5chlorobenzophenone). The remaining peaks may be other metabolites, or they may be substances present in the formulation taken.
Discussion
All the commercially available methods investigated were simple to use and fairly rapid but there was considerable variation in the sensitivity, specificity and reliability of the assays.
The TDx system proved to be the most reliable of the methods evaluated for the preliminary screening ofurines; all opiates found by GC were detected, and 9 urines in which no opiates were found by GC also gave positive results. The TDx is simple to operate and a semi-quantitative result is available in terms of the equivalent concentration of morphine. The main disadvantage of the TDx system is the relatively high reagent cost per sample (about £4) for the assay of one drug or group of drugs. This cost docs, however, include the provision and maintenance of the analytical instrument.
The PFI-20 morphine method appeared to be less specific than the manufacturer claims, giving positive results for 16 samples in which dihydrocodeine (cross-reactivity said to be <0·1'1.,) was the only opioid detected by Gc. It is significant that when samples in which morphine was detected by GC were excluded, 21/24 positive or borderline results by the PFI-20 morphine method were found in samples in which dihydrocodeine had been demonstrated by Gc. A solution of dihydrocodeine (100 rng/L) gave a negative result by this method; a metabolite of dihydrocodeine, dihydromorphine, which could cross-react with the antiserum used in this method," may give false positive results for morphine.
The PFI-20 opiates method failed to detect dihydrocodeine in 3 samples and codeine in one sample; it also gave more unexpected positive results than the other immunoassay techniques. The cost per sample for the PFI-20 methods is about £2 but this does not include the instrument; the current purchase price of the fluorimeter and autosampler is £8740.
The BCL method proved to be unreliable as a preliminary screening procedure for the detection of opiates. False negative results were obtained for several samples containing dihydrocodeine, although the cross-reactivity is reported to be 25'10 relative to morphine. The fact that these samples yielded positive results after dilution cannot be explained. It did not appear to be directly related to the concentration of the drug but it was rather more common at higher concentrations of the major metabolite. This phenomenon was frequently observed during routine screening of urine samples from drug abusers. Testing samples before and after dilution would result in a doubling of the reagent cost of the assay (currently £ 1·25 per sample). The problem of false negative results caused the manufacturers to withdraw certain batches of test packs." False positive results for the detection of opiates by haemagglutination may be obtained if samples are not filtered or centrifuged, if bacterial contamination oceurs or if the working surface is not absolutely free from vibration.?·12.27 It has been reported? that erratic results are obtained if samples stored at 4"C are not allowed to reach room temperature before analysis.
Positive results were given by two or more of the opiates immunoassays in 9 samples in which no opioid other than methadone or dextropropoxyphene was detected by GC (Table 4 ). This did not appear to be due to cross-reaction with methadone and may indicate an opiate present below the detection limits of GC and Toxi-Lab, or an opiate that is not detected by these techniques.
The Toxi-Lab system performed well for the detection of methadone; it was, however, much less successful for morphine, codeine and dihydrocodeine where problems in identification were frequently encountered, and the additional Toxi-Lab tests for morphine were of only limited value. After hydrolysis with p-glucuronidase or the double-migration development procedure there was difficulty in distinguishing between morphine, codeine and dihydrocodeine. In 3 cases, the large amount of interfering material gencrated by the hydrolysis procedure might lead to the misidentification of dihydrocodeine as morphine ( Table 2 ). In the sodium hydroxide procedure, a distinct green colour was observed only when morphine was present in high concentration. The silver nitrate test, which gives a negative result for codeine and dihydrocodeine, was of some value but after hydrolysis it was difficult to identify morphine because of background interference.
The Toxi-Lab system is fairly rapid (about 60 min for one sample) and the analytical procedure 
is simple, but identification of chromatographic patterns can present difficulty, particularly if rnorc than one drug has been taken. The length and complexity of thc analysis are markedly increased if further work has to be performed, such as hydrolysis of conjugates or double migration. The Toxi-Lab system is useful for the detection of a wide range of drugs and metabolites but it is relatively expensive (£4' 50 per sample with additional cost if an alternative developing solvent is required). Capital cost for thc combined Toxi-Lab A and B systems is £1575, which includes the drug compendium (£495), an essential aid to identification, Bcnzodiazepines, and in particular diazepam, are commonly abused by the local drug addict cornmunity.? The polar metabolites arc not readily extracted from urine without prior hydrolysis, so they were not identified either by Toxi-Lab A or GC with the exception oftemazepam, which was detected in 13 samples by Gc. Some benzodiazcpines may be detected in plasma by a complementary Toxi-Lab system (Toxi-Lab B)6 or in urine by Toxi-Lab A after acid hydrolysis.
In the Toxi-Lab system, benzoylccgonine may be masked by a metabolite of dihydrocodeine. The GC was unable to detect benzoylecgonine with sufficient sensitivity despite the use of the special extraction technique recommended for Toxi-Lab." There was no indication for the analysis ofbcnzoylecgonine in any of the samples in this study.
The dual-column GC system is a fairly rapid (about 60 min for one sample) and reliable method of analysis. The technique is more labour-intensive than the immunoassay methods investigated but it yields more information, including identification of individual opiates and many other drugs. It can also be used to obtain an estimate of the concentration of drugs and metabolites present in urine samples, Capillary GC provides an excellent method of separating drugs and metabolites present in biological fluids but the identification of peaks is limited by dependencc on relative retention times. In addition, it is often difficult to obtain samples of pure drug metabolites for the determination of relative retention times. The capital investment is high: the purchase price of a dual-column capillary GC system is about £ 10,000. However, the reagent cost per sample using the method described in this paper is less than £2 and most of this sum represents the cost of a Toxi-Lab extraction tube (£ 1'46). The technique can also be used in screening for other drugs such as those taken in overdose, and gives much improved sensitivity and resolution compared with the packed column system previously described.s" Because of the potentially serious implications, it is essential to minimise the possibility of reporting false positive results for the detection of opiates. It is also important to exclude positive results for low concentrations of opiates due, for example, to ingestion of medicinal preparations, and poppy seeds used for the decoration of bread." For these reasons it may be deemed advisable to use threshold values considerably higher than the limits of detection of immunoassay procedures. Threshold values for unconjugated morphine are set between 0·2 mg/L and 1·0 mg/L for the TDx opiates method, and to 10·0 mg/L and 1·0 mg/L, respectively, for the PFI-20 opiates and PFI-20 morphine methods. It is not possible to set a threshold value for the BCL opiates method which has a limit of detection of 0·05 rng/L 'free' morphine. The higher detection limits of the GC and Toxi-Lab techniques mean that there is no need to set a higher threshold value.
Reports of the screening of urines for drugs issued to clinicians indicate if the opiates immunoassay is positive or negative and list drugs identified by the Toxi-Lab or GC systems. If a positive result is obtained on screening for opiates, but no opiates are detected by the chromatographic procedures, the presence of an unidentified opiate is reported.
Conclusion
Two of the methods investigated, the GC and Toxi-Lab systems, can be used in the analysis of urine for opioids and a wide range of other drugs and metabolites. Both methods identified methadone. In our experience the GC method was more reliable in the discrimination of opiates and the cost per sample considerably less than for the Toxi-Lab system. Both methods are labourintensive, but the laborious process of GC pcak measurement can be eliminated by replacing the chart recorder with a microcomputer. However, with either method there can be difficulty in identification because of the limited specificity of relative retention times in the GC method and failure to identify chromatographic spots in the Toxi-Lab TLC procedure. The identification of drugs and metabolites by GC would be enhanced by the use of a mass-selective detector. 29 -J ' The TDx system was the most reliable and the most expensive ofthc three opiates immunoassay methods. The BCL haemagglutination method, although simple and cheap, was found to be unreliable as previously reported by others." The PFI-20 morphine method lacked the specificity required for unequivocal identification of morphine in urine samples from drug abusers.
We propose that the TDx opiates test (threshold, 0·2 mg unconjugated rnorphinc/L) be used as a preliminary screen in the investigation of drug abuse, further identification being provided by capillary Gc. In the absence of mass-selective detection, Toxi-Lab may be used to provide additional evidence of identification.
The screening of urines for opiates by the Emit system adapted for use on the Cobas Bio (Roche Diagnostics) analyser is being investigated by the authors.
